<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04690569</url>
  </required_header>
  <id_info>
    <org_study_id>MMD010</org_study_id>
    <nct_id>NCT04690569</nct_id>
  </id_info>
  <brief_title>Establish MeMed BV™ Performance for Differentiating Bacterial From Viral Infection in Suspected Acute Infection Patients (APOLLO STUDY)</brief_title>
  <acronym>Apollo</acronym>
  <official_title>Prospective, Multi-Center, Observational, Blinded Study to Establish the Diagnostic Performance of the MeMed BV™ Test for Differentiating Bacterial From Viral Infection in Patients With Suspected Acute Bacterial or Viral Infection (&quot;APOLLO&quot; STUDY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MeMed Diagnostics Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MeMed Diagnostics Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multi-center, observational, blinded study, enrolling pediatric and adult&#xD;
      subjects. Eligible ED\Urgent care and hospital admitted patients with symptoms consistent&#xD;
      with acute bacterial or viral infection and healthy subjects will be recruited according to&#xD;
      the eligibility criteria. Each participant will undergo a thorough investigation upon&#xD;
      recruitment that includes documenting clinical, radiological, laboratory and microbiological&#xD;
      information for determining their health status.&#xD;
&#xD;
      Follow-up data will be collected via a phone call. Diagnostic performance of the MeMed BV™&#xD;
      Test for differentiating bacterial from viral infection will be assessed using an expert&#xD;
      adjudication comparator method.&#xD;
&#xD;
      The study will be run in a blinded fashion: site personnel will be blinded to the comparator&#xD;
      method outcomes, and the expert panel will be blinded to the results of the index test.&#xD;
      Results of the index test will not be revealed to the attending clinician and so will not&#xD;
      influence patient management.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 3, 2019</start_date>
  <completion_date type="Actual">November 22, 2020</completion_date>
  <primary_completion_date type="Actual">November 22, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Establish the diagnostic performance of the MeMed BV™ Test for differentiating bacterial from viral infection using expert adjudication comparator method.</measure>
    <time_frame>Through study completion, an average of 18 months</time_frame>
    <description>Establish the diagnostic performance of the MeMed BV™ Test for differentiating bacterial from viral infection using expert adjudication comparator method.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1384</enrollment>
  <condition>Acute Infection</condition>
  <arm_group>
    <arm_group_label>Infectious</arm_group_label>
    <description>Eligible pediatric and adult patients from ED\Urgent care and hospital admitted, with symptoms consistent with acute bacterial or viral infection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <description>For the purpose of establishing a normal reference range.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MeMed BV</intervention_name>
    <description>The MeMed BV™ Test is an immunoassay that measures three non-microbial (host) proteins (TRAIL, IP-10, and CRP) in adult and pediatric serum samples. The test is intended for use in conjunction with clinical assessments and other laboratory findings as an aid to differentiate bacterial from viral infection. The test is indicated for use in patients presenting to the ED, urgent care center and inpatients with suspected acute bacterial or viral infection. The MeMed BV™ Test generates a numeric score that falls within discrete interpretation bins based on the increasing likelihood of bacterial infection. The MeMed BV™ test is intended for in vitro diagnostic use only.</description>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>Infectious</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Hospital admitted, ED and urgent care center patients over the age of 90 days, with&#xD;
        suspected acute bacterial or viral infection and healthy subjects.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent must be obtained from the patient or his/her legal guardian.&#xD;
             For children under 18 years old, written informed consent from the legal guardian and&#xD;
             assent from the patient (depending on the local requirements)&#xD;
&#xD;
          -  Over 90 days of age&#xD;
&#xD;
          -  Clinical suspicion of acute bacterial or viral infection&#xD;
&#xD;
          -  Temperature ≥ 37.8°C (100°F) (any body site, any measurement device, including&#xD;
             self-reported) or tactile fever, either of them noted at least once within the last 7&#xD;
             days&#xD;
&#xD;
          -  Current disease duration ≤ 7 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Another unrelated episode of febrile infection within the past 2 weeks&#xD;
&#xD;
          -  Suspicion and/or confirmed diagnosis of infectious gastroenteritis/ colitis&#xD;
&#xD;
          -  &gt;48 hours of oral antibiotic treatment&#xD;
&#xD;
          -  &gt;12 hours of intravenous\intramuscular antibiotic treatment&#xD;
&#xD;
          -  HIV, HBV, or HCV infection (self-declared or known from medical records)&#xD;
&#xD;
          -  A proven or suspected infection on presentation with Mycobacterial (e.g. Tuberculosis,&#xD;
             MAC), parasitic or fungal (e.g. Candida, Histoplasma, Aspergillus) pathogen&#xD;
&#xD;
          -  Active inflammatory disease (e.g. IBD, SLE, JIA, RA, Kawasaki, other vasculitis)&#xD;
&#xD;
          -  Major trauma and\or burns in the last 7 days&#xD;
&#xD;
          -  Major surgery in the last 7 days&#xD;
&#xD;
          -  Congenital immune deficiency (CID)&#xD;
&#xD;
          -  Acquired immune deficiency\modulation state including:&#xD;
&#xD;
               -  Active malignancy&#xD;
&#xD;
               -  Current treatment with immune-suppressive or immune-modulating therapies,&#xD;
                  including without limitations:&#xD;
&#xD;
                    -  Administration of P.O.\IV\IM high dose steroids &gt;1mg/kg/day prednisone (or&#xD;
                       equivalent) at some point in the past 10 days or daily continuous use of&#xD;
                       steroids &gt; 0.25 mg/kg/day in the past 7 days&#xD;
&#xD;
                    -  Monoclonal antibodies, anti-TNF agents&#xD;
&#xD;
                    -  Intravenous immunoglobulin (IVIG)&#xD;
&#xD;
                    -  Cyclosporine, Cyclophosphamide, Tacrolimus, Azathioprine, Methotrexate&#xD;
&#xD;
                    -  G/GM-CSF, Interferons&#xD;
&#xD;
               -  Post solid organ/bone marrow transplant patients&#xD;
&#xD;
               -  Asplenia, sickle cell disease&#xD;
&#xD;
          -  Indwelling central venous catheter&#xD;
&#xD;
          -  Cystic Fibrosis&#xD;
&#xD;
          -  Pregnancy- self reported or medically known&#xD;
&#xD;
          -  Other severe illnesses that affect life expectancy and quality of life such as:&#xD;
&#xD;
               -  Severe psychomotor retardation&#xD;
&#xD;
               -  Congenital metabolic disorder&#xD;
&#xD;
               -  End stage renal disease, advanced heart failure (NYHA 3/4), advanced COPD (GOLD&#xD;
                  3/4)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>90 Days</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Family Care Urgent Care</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <zip>29640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Family Care Urgent Care</name>
      <address>
        <city>Powdersville</city>
        <state>South Carolina</state>
        <zip>29611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Family Care Urgent Care</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillel Yaffe Medical Center</name>
      <address>
        <city>Hadera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>3436212</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 24, 2020</study_first_submitted>
  <study_first_submitted_qc>December 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <last_update_submitted>December 30, 2020</last_update_submitted>
  <last_update_submitted_qc>December 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

